title: Methicillin-resistant Staphylococcus aureus: an update.
abstract: Methicillin-resistant Staphylococcus aureus (MRSA) is a serious threat to patients in health care facilities and the community. A MRSA infection can be much more severe than other bacterial infections and can be life-threatening. Resistance to common antibiotics makes treating MRSA costly and difficult. Prolonged hospitalization requiring specialized IV antibiotics also has cost implications. Treatment of MRSA can include use of antibiotics; topical therapies such as honey, topical silver, and gentian violet; and bacteriophages. Research is being conducted on new antibiotics and a MRSA vaccine.
authors.affiliation: Department of Surgery at University, Hospital Lewisham, London, England.
authors.forename: Rajaraman
authors.initials: R
authors.lastname: Durai
authors.forename: Philip C H
authors.initials: PC
authors.lastname: Ng
authors.forename: Happy
authors.initials: H
authors.lastname: Hoque
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002353:Carrier State / Q000382:microbiology / Q000517:prevention & control; D017714:Community-Acquired Infections / Q000382:microbiology; D003428:Cross Infection / Q000382:microbiology; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000276:immunology / Q000472:pathogenicity; D009871:Operating Room Nursing / Q000379:methods; D012307:Risk Factors; D017592:Skin Care / Q000379:methods; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy / Q000635:transmission; D013209:Staphylococcal Vaccines
chemical_list: D000900:Anti-Bacterial Agents; D013209:Staphylococcal Vaccines